25th April 2022 | Pharma Updates
Baddi pharma firm barred from violating on a patent by the HC
High Court has ordered Macleods Pharmaceuticals Limited, Baddi, to refrain from infringing on the patent rights of Boehringer Ingelheim International, Germany under Indian Patent No. 243301.
Domestic pharmaceutical firms' profits may be harmed by rising expenses
Rising input and shipping costs are causing headwinds for domestic pharmaceutical companies, which could have an impact on earnings in the coming quarters.
Pharma companies first to be subjected for safety checks
A third-party safety examination of bulk medication makers has been launched by the state government. This is in response to a number of incidents in the north coastal Andhra region, as well as pressure from environmentalists.
Products from Aurobindo and Sun Pharma recalled in the US market
While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent vitamin B12 deficiency, Sun Pharma is recalling a medicine that is intended to boost the production of natural tears in the eyes.
Ayurveda pharma advertising examined by AYUSH Ministry
Union AYUSH Ministry has directed drug licencing authorities in three states to take appropriate action in response to reports that an Ayurveda pharma giant was using illegal ads to promote medications for heart disease and liver ailments.
Glenmark Pharma announced new FDC for type 2 diabetes
Teneligliptin, a commonly used DPP4 inhibitor, has been combined with Pioglitazone in a novel fixed-dose combination (FDC) for type 2 diabetes in India.
As per Japan Pharma firm, Covid Pill shows rapid virus clearance
According to Phase-2b data from the drug’s Phase II/III clinical study, the pill, S-217622, “demonstrated fast clearance of the contagious SARSCoV-2 virus. “
Alembic Pharma's subsidiary received USFDA approval
Aleor Dermaceuticals Limited (Aleor) has achieved final FDA approval for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%.
